Company Overview and News

1
Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results

2018-04-18 seekingalpha
Today, we will discuss GW Pharmaceuticals (NASDAQ:GWPH), which is up more than 10% after the FDA released briefing documents ahead of the Ad Com meeting to review GWPH's NDA for Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients 2 years or older.
Upvote Downvote

2
Biotech Forum: The Week Ahead

2018-04-09 seekingalpha
There are numerous small cap names presenting mid-stage trial results in the week ahead which could move their stocks.
Upvote Downvote

 
Major Biopharma Catalysts, Conferences and Decisions to Watch For in April

2018-03-31 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which can spell disaster for a stock, comes great reward as well. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.
Upvote Downvote

 
Alder CEO Is Stepping Down

2018-03-21 biospace
Alder BioPharmaceuticals, Inc., located in Bothell, Washington, announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down. It has appointed Paul Cleveland, one of its board members, to act as interim president and chief executive officer, effective immediately.
Upvote Downvote

 
Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer

2018-03-20 globenewswire
BOTHELL, Wash., March 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Paul B. Cleveland, a member of the Company’s Board of Directors, has been appointed to serve as Interim President and Chief Executive Officer, effective immediately. Mr. Cleveland will continue to serve as a director of the Company.
Upvote Downvote

21
Stocks To Watch: Digging For Gems In The Shakeout

2018-02-10 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

2
3 Pharma and Biotech Stocks to Watch Out for in 2018

2018-01-23 investorplace
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. Although the industry continued to face headwinds in the form of drug pricing scrutiny, pricing pressure, increasing competition, concerns regarding Amazon’s interest in entering the healthcare arena, fewer-than-expected acquisition deals and major pipeline setbacks, there were some positive developments as well.
Upvote Downvote

1
Biotech Forum Daily Digest For January 18th

2018-01-18 seekingalpha
There has been some volatile trading action in the biotech sector this week on fears of a government shutdown and potential M&A action.
Upvote Downvote

3
Your Daily Pharma Scoop: Eiger Selloff, Novartis' Cosentyx, RXi Outlines Business Strategy

2018-01-17 seekingalpha
Today we will discuss the results from the phase 2 LIBERTY Study announced by clinical stage biopharmaceutical company, Eiger Biopharmaceuticals (EIGR).
Upvote Downvote

 
Biotech Analysis Central Pharma News: Merck's Keytruda Rises, Celgene's Possible Next Move, Eiger's Phase 2 Dip

2018-01-17 seekingalpha
Merck gains an edge over Bristol-Myers and Roche after positive phase 3 data in first-line non-small cell lung cancer.
Upvote Downvote

 
After an Implosion, Reviewing Analyst Stocks Called to Rise 100% or More

2018-01-16 247wallst
24/7 Wall St. reviews dozens of analyst research reports each day of the week. This ends up being hundreds of analyst calls over the course of a month, and it ends up being thousands of analyst calls over the course of each year. It’s no secret that there is a raging bull market in stocks now that 2018 is underway, and that’s on the heels of the Dow rising 25% and the S&P 500 gaining over 19% in 2017.
Upvote Downvote

 
Why Eiger BioPharma Shares Are Getting Crushed

2018-01-16 247wallst
Shares of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) cratered on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension (PAH) did not meet its primary endpoint. As a result, the company is discontinuing the development of ubenimex in PAH.
Upvote Downvote

 
Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?

2018-01-16 zacks
Intuitive Surgical Inc.’s (ISRG - Free Report) fourth-quarter 2017 results, scheduled for release on Jan 25, are expected to show steady growth in instruments and accessories revenues — one of the major revenue components. While this could majorly drive earnings in the quarter under review, an expected improvement in revenues at all other segments should help the company generate solid results this season.
Upvote Downvote

1
Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation.
Upvote Downvote

 
Eiger BioPharma abandons blood pressure drug after failed study - Channel NewsAsia

2018-01-16 channelnewsasia
REUTERS: Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 15117E107